The impact of additive defects and disorder on the structure and properties of active pharmaceutical ingredient (API) crystals, targeting delivery of more effective drugs that are more efficient and selective.

Defect control of solids is underexploited for molecular systems, but they can affect physical properties and formulation behaviour. Study of disordered pharmaceuticals is highly relevant in understanding pharmaceutical processes and developing these in a sustainable context, improving understanding of API properties and manufacturability issues related to disorder. The characterisation of disordered API's is vital, but my research intresets look to move beyond characterisation to control – can additives and related approaches be used to control defect and disorder formation during crystallisation.